Common Side Effects Patients Report
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, commonly causes upper respiratory infections, diarrhea, and injection-site reactions. These affect 10-20% of users in clinical trials and are usually mild.[1]
Serious Risks from Clinical Data and FDA Warnings
Yes, Cosentyx has been linked to serious side effects, including:
- Infections: Increased risk of severe infections like tuberculosis (TB), invasive fungal infections, and bacterial sepsis due to immune suppression. The FDA label warns of reactivation of latent TB; screening is required before starting.[1][2]
- Inflammatory bowel disease (IBD): New-onset Crohn's disease or ulcerative colitis, sometimes leading to hospitalization or surgery. Post-marketing reports show cases worsening existing IBD.[1]
- Hypersensitivity reactions: Anaphylaxis, angioedema, or urticaria, which can be life-threatening and require immediate discontinuation.[1]
- Neutropenia: Low white blood cell counts, raising infection risk; monitored via blood tests.[1]
In trials, serious infections occurred in 2.7% of Cosentyx users vs. 1.8% on placebo, with higher rates in Crohn's patients.[2]
What Happens During Infections or IBD Flares
Doctors monitor for signs like persistent fever, cough, or abdominal pain. If TB or fungal infection is suspected, treatment stops and antibiotics/antifungals start. IBD cases may need biologics like anti-TNFs or surgery; about 1-2% of users develop new IBD per real-world data.[3]
Who Is at Higher Risk
Patients with history of recurrent infections, IBD, or immunosuppression face elevated risks. The FDA added IBD warnings in 2016 after post-approval reports. Elderly or those on steroids concurrently see more adverse events.[1][2]
Long-Term Safety from Studies
Five-year extension trials (up to 900 weeks) show sustained efficacy but cumulative infection rates up to 59%, with 4.6% serious. No unexpected malignancies, though theoretical cancer risk exists from immune modulation.[2] No direct patent issues tie to safety; Cosentyx's key patents expire around 2032-2034.[4]
[1]: FDA Cosentyx Label
[2]: Novartis Clinical Safety Data
[3]: JAMA Dermatology IBD Analysis
[4]: DrugPatentWatch Cosentyx Patents